Wouter is a venture partner at BGV since 2021. He is currently CEO at Dualyx and will serve in interim management positions in portfolio companies of BGV.
Wouter has over 15 years of Biotech experience, primarily in the business development roles. After starting at Berna Biotech in Switzerland he moved to Crucell, where he was part of the business development team until after the company was acquired by Johnson&Johnson. After 2 years in venture capital at Rabo Private Equity, he moved to Madrid to become the head of business and corporate development at Mabxience. Later he joined NBE Therapeutics as Chief Business Officer, and was instrumental in the sale of the company to Boehringer Ingelheim at the end of 2020.
Wouter holds a MSc in Technical Management from the Delft University of Technology.
MSc Technical Management
NBE Therapeutics, Mabxience, Rabo Private Equity Crucell, Johnson&Johnson,